A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Phase 1

Recruiting

• Conditions: NSCLC (Non-small Cell Lung Cancer); Solid Tumor
• Interventions: Drug: YH42946

• Registration Number: NCT06616766
• Lead Sponsor: Yuhan Corporation

Brief Summary

The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.

Detailed Description

YH42946 is a novel, orally available tyrosine kinase inhibitor targeting HER2. YH42946 showed potency for diverse HER2 aberrations including HER2 overexpression, amplification, or mutation, as well as EGFR Ex20ins.

This is a Phase 1/2, open-label, multicenter, first-in-human study of YH42946. The study has 2 parts. The first part is dose escalation part to identify the maximum tolerated dose. The second part is dose expansion part to select 2 doses for RD selection at the first cohort, after then RD will be determined to ensure its efficacy. Several independent cohorts are planned.

Study Timeline

• Study First Submitted: 2024-09-23
• Study First Submitted QC: 2024-09-26
• Study First Posted: 2024-09-27
• Study Start: 2024-10-02
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-12
• Last Update Posted: 2024-11-14
• Primary Completion: 2028-03-15
• Study Completion: 2028-07-29

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 161

Inclusion Criteria

• ECOG performance status 0 or 1

• Estimated life expectancy of at least 3 months

• Patients who have progressed on or after all available standard therapies or for whom standard treatment is inappropriate

• Mandatory provision of archived or fresh tumor tissue in quantity sufficient to allow for retrospective confirmation of HER2 or EGFR mutation

• A patient with a history of brain metastases must have had all lesions treated

• Adequate organ function defined as all of the following:

  • Adequate bone marrow function (within 1 week prior to first administration): Neutrophils≥1.5 x10*9 cells/L (Criteria must be met without the use of Granulocyte-Colony Stimulating Factor (G-CSF) within last week prior to testing.); platelet count≥75 x10*9 cells/L; Hb ≥9g/dL (Criteria must be met without packed red blood cell (pRBC) transfusion within last week prior to testing.)
  • Adequate hepatic function: Serum bilirubin≤1.5 x upper limit of normal (ULN), and serum transaminase (either aspartate transaminase (AST) or alanine transaminase (ALT)) ≤ 3 x ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases (within 1 week prior to first administration)
  • Adequate renal function: Serum creatinine ≤ 1.5 x ULN or Estimated glomerular filtration rate (eGFR) > 60 mL/min per 1.73 m*2 according to the site's calculation method.

[Dose Escalation part only]

• Histologically or cytologically confirmed diagnosis of advanced, and/or metastatic non-hematologic malignancy
• Documented HER2 or EGFR mutation (HER2 tyrosine kinase domain mutation or EGFR exon 20 insertion, HER2 amplification or overexpression)

[Dose Expansion part only]

• Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC HER2 exon 20 insertion (Cohort 1)

Read More

Exclusion Criteria

• Patient with symptomatic or progressive brain metastases

• Known or suspected leptomeningeal disease (LMD)

• Uncontrolled spinal cord compression

• History of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks

• History of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system

• Medical, psychiatric, cognitive or other conditions that compromise the patients ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study

• Any severe concurrent disease or condition (includes active infections, cardiac arrhythmia) that in the judgment of the Investigator would make study participation inappropriate for the patient

• History of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis

• History of a second primary cancer with the exception of

  1. curatively treated non-melanomatous skin cancer,
  2. curatively treated cervical or breast carcinoma in situ, or
  3. other malignancy with no known active disease present and no treatment administered during the last 2 years

• Infection with human immunodeficiency virus (HIV) or active chronic hepatitis B or hepatitis C

• Major surgery within 4 weeks prior to the first dose of study treatment

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Part 1 and Part 2	YH42946	Part 1: Dose escalation arm to determine the MTD Part 2: Dose expansion part to select RD. Several independent cohorts are planned.

Primary Outcome Measures

Name	Time	Method
Treatment Emergent Adverse Events(TEAE)s	Through study completion, during the first 21 days of DLT evaluation period.	To assess the safety and tolerability of YH42946
Objective Response Rate (ORR)	Through dose expansion part completion, approximately 12 months	Anti-tumor activity according to RECIST v1.1

Secondary Outcome Measures

Name	Time	Method
AUClast	Through study completion, approximately 12 months	To characterize the pharmacokinetics (PK) of YH42946
AUCinf	Through study completion, approximately 12 months	To characterize the pharmacokinetics (PK) of YH42946
Cmax	Through study completion, approximately 12 months	To characterize the pharmacokinetics (PK) of YH42946
Tmax	Through study completion, approximately 12 months	To characterize the pharmacokinetics (PK) of YH42946
Objective Response Rate (ORR)	Through study completion, approximately 12 months	To assess the anti-tumor activity according to RECIST v1.1

Trial Locations

Locations (6)

Next Oncology Virginia; 🇺🇸 Fairfax, Virginia, United States

Seoul National University Bundang Hospital; 🇰🇷 Seongnam-si, Gyeonggi-do, Korea, Republic of

The Catholic Univ. of Korea St. Vincent's Hospital; 🇰🇷 Suwon-si, Gyeonggi-do, Korea, Republic of

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of

Severance Hospital, Yonsei University; 🇰🇷 Seoul, Korea, Republic of